Toho : Notice of “Proposal for Business Continuity Plan in the Supply of Pharmaceuticals” by the Study Group for the Establishment of BCP System(114 KB)

	October 24, 2023
To whom it may concern:
Company Name:	TOHO HOLDINGS CO., LTD.
Corporate	Atsushi Udoh, Representative
Representative:	Director, CEO
	(Prime Market of Tokyo Stock
	Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Corporate Officer
	and General Manager, Corporate
	Communications and Investor
	Relations Division
	(TEL: [phone])

Notice of "Proposal for Business Continuity Plan in the Supply of Pharmaceuticals"

by the Study Group for the Establishment of BCP System

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO: Atsushi Udoh) is pleased to announce that the Study Group for the Establishment of BCP System (hereinafter, the Study Group), which it established with the participation of TOHO PHARMACEUTICAL CO., LTD. (Headquarters: Tokyo; President and Representative Director: Akira Umada; hereinafter "TOHO PHARMACEUTICAL"), its wholly owned subsidiary engaged in pharmaceutical wholesaling, pharmaceutical companies, and others, has studied a business continuity plan and compiled it as a "Proposal for Business Continuity Plan in the Supply of Pharmaceuticals" as detailed below.

The Company's social mission is to provide a stable supply of pharmaceuticals and other products even in times of emergency, such as disasters and pandemics. We have advanced our logistics functions by utilizing cutting-edge technology and promoted construction of a robust business infrastructure capable of centrally managing information of our sales offices and distribution centers nationwide. As a result, we were able to quickly resume the supply of pharmaceuticals in the event of a large-scale disaster in Japan, such as an earthquake or heavy rain.

However, it is anticipated that the supply of products from pharmaceutical companies to us may be disrupted due to unforeseen circumstances in the event of a disaster, making it all the more important to establish a business continuity plan for the entire supply chain that goes beyond the framework of the company. Therefore, with the purpose of building a more stable pharmaceutical supply system in the event of a disaster, with TOHO PHARMACEUTICAL's ability to recover from a disaster as its core, we established the Study Group, together with pharmaceutical companies and others that supported our purpose, to study a business continuity plan.

Based on the idea that the business continuity plan should be developed, shared, and updated jointly with many stakeholders involved in the supply of pharmaceuticals, and that the effectiveness of the plan should be enhanced through drilling, the outline of the study conducted by the Study Group has been compiled as a "Proposal for Business Continuity Plan in the Supply of Pharmaceuticals."

In the future, we will prepare to submit this Proposal to public authorities and local governments. At the same time, we will jointly study and examine more specific business continuity plans that take various situations into consideration.